| Literature DB >> 27063555 |
Ludovica Monti1, Azzurra Stefanucci2, Stefano Pieretti3, Francesca Marzoli3, Lorenzo Fidanza3, Adriano Mollica4, Sako Mirzaie5, Simone Carradori4, Luciano De Petrocellis6, Aniello Schiano Moriello6, Sándor Benyhe7, Ferenc Zádor7, Edina Szűcs7, Ferenc Ötvös7, Anna I Erdei7, Reza Samavati7, Szabolcs Dvorácskó7, Csaba Tömböly7, Ettore Novellino8.
Abstract
Fentanyl is a powerful opiate analgesic typically used for the treatment of severe and chronic pain, but its prescription is strongly limited by the well-documented side-effects. Different approaches have been applied to develop strong analgesic drugs with reduced pharmacologic side-effects. One of the most promising is the design of multitarget drugs. In this paper we report the synthesis, characterization and biological evaluation of twelve new 4-anilidopiperidine (fentanyl analogues). In vivo hot-Plate test, shows a moderate antinociceptive activity for compounds OMDM585 and OMDM586, despite the weak binding affinity on both μ and δ-opioid receptors. A strong inverse agonist activity in the GTP-binding assay was revealed suggesting the involvement of alternative systems in the brain. Fatty acid amide hydrolase inhibition was evaluated, together with binding assays of cannabinoid receptors. We can conclude that compounds OMDM585 and 586 are capable to elicit antinociception due to their multitarget activity on different systems involved in pain modulation.Entities:
Keywords: FAAH enzyme; Fentanyl; MAGL enzyme; opioids; pain
Mesh:
Substances:
Year: 2016 PMID: 27063555 DOI: 10.3109/14756366.2016.1160902
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051